The European Medicines Agency (EMA) is evaluating the possible administration in the European Union (EU) of the Covid-19 vaccine from Moderna to children aged 6 to 11 years, was released this Wednesday, 10 November.
In a press release, the EMA reports that it has begun "to evaluate an application to extend the use of the vaccine for Moderna's covid-19, Spikevax, to children aged 6 to 11 years".
The EMA's Human Medicines Committee will review data on the vaccine, including the results of an ongoing clinical study involving children aged 6 to 11 years, to decide whether or not to recommend extending its use.
The EMA anticipates issuing an opinion within two months.
Spikevax is a vaccine for the prevention of covid-19, currently authorized for use in people 12 years of age and older.
It contains a molecule called messenger RNA (mRNA) with instructions for making a protein, known as the spike protein, which is naturally present in SARS-CoV-2, the virus that causes Covid-19.
The vaccine works by preparing the body to defend itself against SARS-CoV-2.
As of October 18, the agency had already started a similar evaluation process for Pfizer/BioNTech's Cominarty vaccine.
Comments